FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Gitelman Igor
2. Date of Event Requiring Statement (MM/DD/YYYY)
2/11/2021 

3. Issuer Name and Ticker or Trading Symbol

Advaxis, Inc. [ADXS]
(Last)        (First)        (Middle)

C/O ADVAXIS, INC., 305 COLLEGE ROAD EAST
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                          _____ 10% Owner
___X___ Officer (give title below)        _____ Other (specify below)
Chief Accounting Officer /
(Street)

PRINCETON, NJ 08540      

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Employee Stock Option (right to buy)  (1)11/16/2030 Common Stock 50000 $0 D  

Explanation of Responses:
(1) The option is subject to three-year vesting with one-third vesting on November 16, 2021, one-third on November 16, 2022 and the final one-third vesting on November 16, 2023, subject to the reporting persons continued service to Advaxis, Inc. (the "Company") on the applicable vesting date and the terms and conditions of the Company's 2015 Incentive Plan

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Gitelman Igor
C/O ADVAXIS, INC.
305 COLLEGE ROAD EAST
PRINCETON, NJ 08540


Chief Accounting Officer

Signatures
/s/ Igor Gitelman2/16/2021
**Signature of Reporting PersonDate

Ayala Pharmaceuticals (QX) (USOTC:ADXS)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Ayala Pharmaceuticals (QX) Charts.
Ayala Pharmaceuticals (QX) (USOTC:ADXS)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Ayala Pharmaceuticals (QX) Charts.